Stock Ratings / Health Care / PROF / forecast

UTMD (63) KTWO (53) PDEX (51) STIM (31) ⌘ Pro Terminal →

Profound Medical Corp. (PROF) 12-Month Stock Forecast & Price Target Cone

$5.86 +1.38% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.86

Profound Medical Corp. (PROF) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $214.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.86 (+0.06%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-4.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PROF)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (47/100 Composite)

🔍 WHY PROF SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (30% of score)

Altman Z-Score 5.97 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (26% of score)

FRED Regime × Technicals: 26% of 52W Range • RSI-14 at 58.7 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$6.90-12.9% Next Q

Q2 (-2Q)

Grade C-$6.01-7.5% Next Q

Q3 (-1Q)

Grade C-$5.56+5.4% Next Q

Current

Grade D$5.86-5.9% Hist 90D α

Trajectory: C (55) → D (47)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PROF Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PROF currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.23) and Max Pain ($6.15) forces dealer call-delta covering toward $9.40.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PROF• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PROF Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 47%NO 53%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your PROF Position Size: $10,000

Shares at $5.86: 1706.5 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $4.34

$7,406

$-2,594 (-25.9%)

12M Consensus BaseTarget $5.57

$9,505

$-495 (-4.9%)

12M Bull Case BreakoutTarget $9.40

$16,041

+$6,041 (+60.4%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$6	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$9	69%	B
JP MorganUS Large-Cap Research	SELL	$5	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PROF)

✓Walkthrough of PROF's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PROF // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -12.54%📐 HORIZONTAL RANGE

2026-10-30O $5.94H $6.63L $5.86C $5.86VOL 475.4K

RES: $7.40SUP: $5.09SMA50: $6.23SMA200: $6.67

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PROF Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PROF Butterfly Map → + Track PROF →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +65.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PROF today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PROF. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PROF today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PROF)

Health Care Rank #413 of 1016 ⚔️ UTMD vs PROF Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PROF vs. UTMD, KTWO, PDEX, STIM)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Profound Medical Corp. (PROF) ranks #413 by composite RQD confidence (47/100, grade D) and #565 by equity capitalization ($214.1M). Within this direct 5-issuer industry benchmark cohort, PDEX leads on earnings valuation at 22.2x trailing P/E, while UTMD leads on capital efficiency and profitability with 26.9% ROIC and 57.1% gross margin. UTMD currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with PROF at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PROF ACTIVE Profound Medical Corp.	D	47/100	—	70.8%	-35.0%	+1.38%	$214.1M	Benchmark Subject
UTMD Utah Medical Products Inc.	C	63/100	—	57.1%	26.9%	-2.96%	$212.7M	/utmd-vs-prof →
KTWO K2 Capital Acquisition Corporation Class A Ordinary Share	D+	53/100	—	—	—	+0.30%	$202.8M	/ktwo-vs-prof →
PDEX Pro-Dex Inc.	D	51/100	22.2x	29.3%	23.2%	-2.52%	$199.2M	/pdex-vs-prof →
STIM Neuronetics Inc.	E	31/100	—	48.5%	-35.0%	+5.31%	$181.3M	/stim-vs-prof →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001628808

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Profound Medical Corp. (PROF) reported GAAP revenue of $16.1M (+65.3% vs. FY2024 revenue of $9.7M , and +172.9% cumulative change since FY2023) , GAAP net income of -$42.6M, operating cash flow of -$38.2M, and free cash flow of -$38.4M (-63.7% YoY). On the balance sheet, PROF closed FY2025 with $77.5M in total assets against $4.5M in total debt (Altman Z-Score: 5.97, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$16.1M	-$42.6M	-$38.2M	-$38.4M	$77.5M	$4.5M
FY2024 (FY)	2024-12-31	$9.7M	-$27.8M	-$23.5M	-$23.5M	$70.2M	$2.9M
FY2023 (FY)	2023-12-31	$5.9M	-$28.3M	-$22.6M	-$22.6M	—	—

3. PROF Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PROF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Profound Medical Corp. (NASDAQ: PROF) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $5.86 (+1.38% 1D, market cap $214.1M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PROF ranks #413 in composite RQD confidence.

How does PROF compare to UTMD and KTWO in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), PROF carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 70.8%, and ROIC of -35.0%. By comparison, UTMD (Utah Medical Products Inc.) holds a C grade (63/100 RQD, P/E N/A, ROIC 26.9%, cap $212.7M) and KTWO (K2 Capital Acquisition Corporation Class A Ordinary Share) posts a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $202.8M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PROF?

Per PROF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001628808), Profound Medical Corp. generated $16.1M in revenue (+65.3% YoY), -$42.6M in net income, and -$38.4M in free cash flow against $77.5M in total assets and $4.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PROF trading relative to its 50-day, 200-day, and 52-week technical levels?

PROF last traded at $5.86 (+1.38% on volume of 67,425 shares), positioning the stock -5.94% below its 50-day simple moving average ($6.23) and -12.14% below its 200-day simple moving average ($6.67). Across its 52-week range of $4.80 to $8.95, PROF sits at the 25.5% percentile with a 14-day RSI of 58.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($5.13 to $6.59).

PROF Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is PROF's 12-month stock price target?

Profound Medical Corp. (PROF) carries a 12-month consensus base price target of $5.57 (-4.9% from $5.86), with a bull-case target of $9.4 and a bear-case floor of $4.34.

Is PROF stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates PROF D (Sell — SELL) with an RQD Confidence score of 47/100.

Direct Sub-Reports: PROF RQD Cockpit PROF 12M Forecast PROF Earnings & Move PROF Dividends & DRIP PROF Insiders & 13F PROF Whale Options PROF Profit Sankey PROF News & Why